March 8, 2017 / 9:43 PM / in 5 months

BRIEF-Opthea says completed a Type C meeting with the U.S. FDA

March 9 (Reuters) - Opthea Ltd:

* Anticipates reporting of outcomes from ongoing phase 2a dose expansion cohorts of clinical trial by end of March 2017

* Completes FDA meeting to inform opt-302 wet amd clinical program Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below